Synthesis and optimization of ceftriaxone-loaded solid lipid nanocarriers

Kumar, Sandeep; Bhanjana, Gaurav; Kumar, Ajay; Taneja, Kapila; Dilbaghi, Neeraj; Kim, Ki‐Hyun

doi:10.1016/j.chemphyslip.2016.09.002

Cited by 42 publications

(31 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this manner, nanoformulation provides drug contact for enhanced period as compared to that of pure metformin. It is quite clear from Figure that MLANs have released drug up to 30 h. This study clearly reflects the controlled/sustained release properties of formulations prepared at nanoscale …”

Section: Resultssupporting

confidence: 68%

“…MLANs have released drug up to 30 h. This study clearly reflects the controlled/sustained release properties of formulations prepared at nanoscale. [15,34]…”

Section: In-vitro Drug Release Profilementioning

confidence: 99%

“…[15,16] Polymers have commonly been recommended as the best choice for the encapsulation of a variety of guest molecules including drugs because they are biodegradable and biocompatible while releasing desired cargo via diverse means including change in pH, temperature, surface modification, and conjugation. [15][16][17] Naik and Jignesh [18] prepared pH-responsive nanoparticles to increase the dissolution of an antiviral drug. Zhu et al [19] also reported antibody-conjugated chitosan nanoparticles for drug targeting to enhance antineoplastic activity.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Metformin-loaded alginate nanoparticles as an effective antidiabetic agent for controlled drug release

Kumar

Bhanjana

Verma

et al. 2017

Journal of Pharmacy and Pharmacology

Self Cite

View full text Add to dashboard Cite

The drug loading and encapsulation efficiency in MLANs were 3.12 mg (the amount of metformin added in 100 mg of nanoparticles) and 78%, respectively. The results of in-vitro drug release studies and in-vivo efficacy tests (using animal models) demonstrated enhanced efficiency and response of MLANs relative to pure metformin. The efficacy of MLANs (46.8 mg/kg) was overall about three times higher than that of pure metformin150 mg/kg.

show abstract

Section: Resultssupporting

confidence: 68%

“…MLANs have released drug up to 30 h. This study clearly reflects the controlled/sustained release properties of formulations prepared at nanoscale. [15,34]…”

Section: In-vitro Drug Release Profilementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Metformin-loaded alginate nanoparticles as an effective antidiabetic agent for controlled drug release

Kumar

Bhanjana

Verma

et al. 2017

Journal of Pharmacy and Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ceftriaxone sodium is an antibiotic commonly used for the treatment of bacterial infection such as middle ear infection, meningitis, bone, and joint infection, intraabdominal infection, skin infection, and pelvic inflammatory diseases [1]. Ceftriaxone vials are among the most prevalent types of antibiotics with the highest mortality rate due to the injection of vials [2].…”

Section: Introductionmentioning

confidence: 99%

“…Ceftriaxone vials are among the most prevalent types of antibiotics with the highest mortality rate due to the injection of vials [2]. Ceftriaxone produces several side effects such as diarrhea, elevated liver enzymes, blood urea nitrogen, eosinophilia, thrombocytosis, and other local reactions [1]. Given the inevitability of using this antibiotic in today's health care system, it is essential to develop new prodrugs [1].…”

Section: Introductionmentioning

confidence: 99%

Enhanced bactericidal effect of ceftriaxone drug encapsulated in nanostructured lipid carrier against gram-negative Escherichia coli bacteria: drug formulation, optimization, and cell culture study

Ebrahimi

Farhadian

Karimi

et al. 2020

Antimicrob Resist Infect Control

View full text Add to dashboard Cite

Background: Ceftriaxone is one of the most common types of antibiotics used to treat most deadly bacterial infections. One way to alleviate the side effects of medication is to reduce drug consumption by changing the ordinary drug forms into nanostructured forms. In this study, a nanostructured lipid carrier (NLC) containing hydrophilic ceftriaxone sodium drug is developed, and its effect on eliminating gram-negative bacteria Escherichia coli death is investigated.Methods: Double emulsion solvent evaporation method is applied to prepare NLC. Mathematical modeling based on the solubility study is performed to select the best materials for NLC preparation. Haftyzer-Van Krevelen and Hoy's models are employed for this purpose. Drug release from optimized NLC is examined under in vitro environment. Then, the efficacy of the optimized sample on eliminating gram-negative bacteria Escherichia coli is investigated. Results: Mathematical modeling reveals that both methods are capable of predicting drug encapsulation efficiency trends by chaining solid and liquid lipids. However, Haftyzer-Van Krevelen's method can precisely predict the particle size trend by changing the surfactant types in water and oily phases of emulsions. The optimal sample has a mean particle size of 86 nm and drug entrapment efficiency of 83%. Also, a controlled drug release in prepared nanostructures over time is observed under in-vitro media. The results regarding the effectiveness of optimized NLC in killing Escherichia coli bacteria suggests that by cutting drug dosage of the nanostructured form in half, an effect comparable to that of free drug can be observed at longer times. Conclusion: Results confirm that NLC structure is an appropriate alternative for the delivery of ceftriaxone drug with a controlled release behavior.

show abstract

The contribution of nano‐based strategies in overcoming ceftriaxone resistance: a literature review

Yayehrad

Marew

Birhanu

2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Antimicrobial drug resistance, including resistance to multiple antibiotics, is continuously increasing. According to research findings, many bacteria resistant to other antibiotics were susceptible to ceftriaxone. However, over the last few years, ceftriaxone resistance has become growing and extremely worrisome challenge to the global healthcare system and several strategies have been initiated to contain the spread of antimicrobial drug resistance. Its extended use for therapeutic or preventative measures in humans and farm animals resulted in the development and spread of resistance. Recent advances in nanotechnology also offer novel formulations based on distinct types of nanostructure particles with different sizes and shapes, and flexible antimicrobial properties. For ceftriaxone, several nanostructured formulations through conjugation, intercalation, encapsulation with lipid carrier, and polymeric films have been investigated by different groups with promising results in combating the development of resistance. This review addressed the existing knowledge and practice on the contribution of nano‐based delivery approaches in overcoming ceftriaxone resistance. Evidences have been generated from published research articles using major search electronic databases such as PubMed, Medline, Google Scholar, and Science Direct.

show abstract

Synthesis and optimization of ceftriaxone-loaded solid lipid nanocarriers

Cited by 42 publications

References 33 publications

Metformin-loaded alginate nanoparticles as an effective antidiabetic agent for controlled drug release

Metformin-loaded alginate nanoparticles as an effective antidiabetic agent for controlled drug release

Enhanced bactericidal effect of ceftriaxone drug encapsulated in nanostructured lipid carrier against gram-negative Escherichia coli bacteria: drug formulation, optimization, and cell culture study

The contribution of nano‐based strategies in overcoming ceftriaxone resistance: a literature review

Contact Info

Product

Resources

About